1. Wang, Q, Bi, W, Zhu, X, Li, H, Qi, Q, Yu, F, Lu, L, Jiang, S. Non-neutralizing antibodies induced by HIV-1 gp41 NHR domain gain neutralizing activity in the presence of HIV fusion inhibitor enfuvirtide: a potential therapeutic vaccine strategy. J Virol , 2015; 89(13):6960-6964. IF=4.439

2. Li, W, Wang, Q, Li, Y, Yu, F, Liu, Q, Qin, B, Xie, L, Lu, L, Jiang, S. A Nanoparticle-Encapsulated non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma. Curr Pharm Des, 2015; 21(7):925-935. IF=3.452

3. Li, H, Ying, T, Yu, F, Lu, L, Jiang, S. Development of therapeutics for treatment of Ebola virus infection. Microbes Infect, 2015; 17(2):109-117. IF=2.861

4. Liu, Q, Xia, S, Sun, Z, Wang, Q, Du, L, Lu, L, Jiang, S. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob. Agents Chemother.  2015, 59(1):742-4. IF=4.451

5. Sun Z, Wang Q, Jia R, Xia S, Li Y, Liu Q, Xu W, Xu J, Du L, Lu L, Jiang S. Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. Viruses. 2015 7(2):798-819. IF=3.279

6. He B, Zheng BJ, Wang Q, Du L, Jiang S, Lu L. Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. Microbes Infect. 2015;17:135-141.IF=2.731

7. Liu H, Bi W, Wang Q, Lu L, Jiang S. Receptor binding domain based HIV vaccines. Biomed Res Int. 2015; 2015:594109. IF=2.706